Definitive Contract 75A50124C00036

<p>This is a $323,554,976.00 Firm Fixed Price definitive contract awarded by the Office of the Assistant Secretary for Preparedness and Response, a civilian agency, to Paratek Pharmaceuticals, Inc. for the development of an antibiotic to treat a biothreat indication. The contract has an ultimate completion date of December 17, 2029 and was awarded on December 18, 2019. This contract is not associated with a set-aside program.</p>

<p>This is a $205,003,103.62 cost-plus-fixed-fee definitive contract awarded by the Office of the Assistant Secretary for Preparedness and Response, a civilian agency, to Modex Therapeutics, Inc. to advance the development of potent, cross-reactive multispecific antibodies for the preparedness countermeasure of COVID-19 and seasonal and highly pathogenic avian influenza. The contract has an ultimate completion date of January 18, 2030. This award is not a set-aside contract.</p>

<p>This is a Cost Plus Fixed Fee contract awarded by the Office of the Assistant Secretary for Preparedness and Response, a civilian agency, to Altimmune, Inc. for the development of a single-dose intranasal vaccine for post-exposure prophylaxis of inhalation anthrax. The award has a ceiling value of $135,880,962.00 and a period of performance through December 31, 2021. The contract was awarded on July 27, 2016 and does not have a set-aside designation.</p>

This federal contract award, valued at $330,136,246.14, was granted by the Office of the Assistant Secretary for Preparedness and Response (ASPR), a civilian agency within the U.S. Department of Health and Human Services, to 4J Therapeutics Inc., a self-certified small disadvantaged business. The contract's objective is to demonstrate the versatility and efficacy of 4J Therapeutics' programmable antiviral technology platform by assembling a preclinical package for LNA14, performing a Phase 1a...

This is a definitive contract awarded by the Department of Health and Human Services (HHS) Office of the Assistant Secretary for Preparedness and Response to Elusys Therapeutics Inc., a self-certified small disadvantaged business and manufacturer of goods, for the delivery of ANTHIM (obiltoxaximab). The contract has a firm fixed price of $124,650,623.00 and a completion date of April 30, 2027. There is no set-aside designation for this contract. Elusys Therapeutics Inc. is a subsidiary of the...

This is a $4,590,862.00 cost-plus-fixed-fee definitive contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency, to Sorrento Therapeutics, Inc., a small disadvantaged business. The contract is for the &quot;DEVELOPMENT OF IN VITRO FOR BIODEFENSE, ANTIMICROBIAL RESISTANT (AMR) INFECTIONS AND EMERGING INFECTIOUS DISEASES&quot;, which was a Broad Agency Announcement (BAA) research area. The contract has a period of performance through May 2, 2025...

This is a federal contract award from the U.S. Department of Health and Human Services (HHS) to Elusys Therapeutics Inc., a for-profit organization and manufacturer of goods. The contract, valued at $44,971,900.00, is for &quot;OTHER FUNCTIONS&quot; and is a Firm Fixed Price Delivery Order with no set-aside designation. Elusys Therapeutics Inc. specializes in biomedical research and development, with a focus on advanced technology. The contract is related to the &quot;ANTHIM&quot; product, which...

This is a $4,469,522.01 cost-plus-fixed-fee definitive contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency, to Agile Sciences, Inc., a small disadvantaged business. The contract is for &quot;Targeting Therapeutics Development to Relieve Bottlenecks: Optimizing Lead Therapeutic Compounds Against Infectious Pathogens&quot; and has an ultimate completion date of October 15, 2018. The contract was awarded on June 30, 2015 and was not set aside.

This is a Firm Fixed Price definitive contract awarded by the Office of the Assistant Secretary for Preparedness and Response, a civilian agency, to Medimmune LLC for the procurement of storage and stability study of live attenuated master and working seed lot(s) for preparedness and response. The contract has a ceiling value of $94,705.27 and a completion date of February 21, 2027. The contract is not set aside for any specific business type. This contract award is not associated with a...

This is a firm fixed-price purchase order awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency within the U.S. Department of Health and Human Services, to Creative Dynamics, Inc. (DBA Creative Biolabs) for the acquisition of recombinant human anti-influenza A virus (IAV) antibody in a 5mg quantity. The contract has a ceiling value of $7,960.00 and was awarded on October 31, 2017, with a planned completion date of January 31, 2018. This contract does not...